IL6 and pancreatic neoplasm: Additionally, elucidating the relationship between IL-6 and systemic inflammatory biomarkers may help characterize the features of pancreatic cancer that are commonly known to be unresponsive to immunotherapy, potentially leading to new therapeutic strategies.